Evidence map›Paper›PMID 32972383›Full record

ArticleBMC cancer2020

Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers.

Chunmei Fan, Jinpeng Wang, Yanyan Tang, Shanshan Zhang, Fang Xiong, Can Guo, Yanhong Zhou, Zheng Li, Xiaoling Li, Yong Li and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. The role of exosomal long non-coding RNAs in head, neck and thyroid cancers.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Deciphering the role ofJournal of translational internal medicine · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Chunmei FanDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078.
Jinpeng WangDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078.
Yanyan TangThe Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China.
Shanshan ZhangDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078.
Fang XiongDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078.
Can GuoThe Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China.
Yanhong ZhouThe Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China.
Zheng LiThe Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China.
Xiaoling LiThe Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, China.
Yong LiDepartment of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Guiyuan LiDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078.
Zhaoyang ZengDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078. zengzhaoyang@csu.edu.cn.
Wei XiongDepartment of Stomatology, NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, No.88 Xiangya Road, Changsha, Hunan, P. R. China, 410078. xiongwei@csu.edu.cn.
Central South University · CNXiangya Hospital Central South University · CNBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdentification of effective diagnostic and prognostic biomarkers of cancer is necessary for improving precision medicine. Long non-coding RNAs (lncRNAs) play an important regulatory role in tumor initiation and progression. The lncRNA LOC284454 is distinctly expressed in various head and neck cancers (HNCs), as demonstrated by our previous bioinformatics analysis. However, the expression levels and functions of LOC284454 in cancer are still unclear.

methodsWe investigated the dysregulation of lncRNAs in HNCs using the GEO database and found that LOC284454 was highly expressed in HNCs. Serum samples from 212 patients with HNCs and 121 normal controls were included in this biomarker study. We measured the expression of LOC284454 in the sera of HNC patients and normal controls using RT-qPCR. Receiver operating characteristics (ROC) analysis is an important statistical method that is widely used in clinical diagnosis and disease screening. ROC was used to analyze the clinical value of LOC284454 in the early diagnosis of HNCs.

resultsLOC284454 was significantly upregulated in the sera of patients with nasopharyngeal carcinoma, oral cancer, and thyroid cancer. LOC284454 upregulation had good clinical diagnostic value in these cancers, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834, respectively.

conclusionsLOC284454 may be a valuable serum biomarker for HNCs facilitating the early diagnosis of malignant cancers. Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs. This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.

Indexed as

Biomarkers, TumorFemaleHead and Neck NeoplasmsHumansMaleMouth NeoplasmsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRNA, Long NoncodingThyroid NeoplasmsUp-RegulationBiomarkers, TumorRNA, Long NoncodingHead and neck cancersLong noncoding RNAsReceiver operating characteristicSerum biomarker

Identifiers

PMID32972383
PMCPMC7517628
OpenAlexW3089031151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.